• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

70
9
8
8
3

COUNTRY

8
1
1

PRICE

7
10
37
122

PUBLISHED

0
2
18
122

PRODUCT TYPE

117
4
1

Breast Cancer

(122 Products)

Over a million women worldwide are diagnosed with breast cancer annually. Alongside surgery, radiotherapy and immunotherapy, pharmaceutical products (including hormonal therapy and chemotherapy) are in the frontline against this terrible disease. Market reports in this section enable buyers to read up on the latest breast cancer drug pipelines and R&D strategies, as well as the medical and commercial activities of major players and niche operators such Abraxis Bioscience, Aeterna Zentaris, Agendia BV, Aphton Corp, Array BioPharma, AstraZeneca Plc, Bristol Myers Squibb, Dendreon Corporation, Eli Lilly, Genentech, Genta, Novartis AG, Pfizer, Roche Group, Sanofi-Aventis, Schering AG, Therion Biologics, and ViRexx Medical. Also included are cutting edge academic journals and various expert textbooks for medical professionals involved in breast cancer treatment. Show Less Read more

HER-2 Positive Breast Cancer Market in the US 2015-2019

About HER-2 Positive Breast Cancer Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer...

March 2015
FROM

Global HER-2 Positive Breast Cancer Market 2015-2019

About HER-2 Positive Breast Cancer Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer...

March 2015
FROM

Breast Cancer Screening (Mammography, MRI & Ultrasound) Market & Forecast – Worldwide

Breast cancer is the most common cancer among women in both the developed and developing world. Worldwide Breast Cancer Screening Market was in double digit Billion US$ for 2013. United States is the...

September 2014
FROM

Global Breast Cancer Market 2014-2018

About Breast Cancer Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically,...

June 2014
FROM

Breast Cancer Therapies Markets

Breast cancer therapies are entering a new era as game-changers emerge for each of the major breast cancer patient populations New market entrants must possess drug profiles and a savvy clinical development...

November 2012
FROM

Mammography World Markets

Breast cancer is the most common type of cancer in women, affecting one in eight during their lives Mammography is the most valuable method for detecting potentially cancerous anomalies in the breast...

December 2012
FROM

Breast Cancer Pipeline Highlights - 2015

The latest report Breast Cancer Pipeline Highlights – 2015 Update, provides most up-to-date information on key pipeline molecules in the global Breast Cancer market. It covers emerging therapies for...

July 2015
FROM

Breast Cancer Drug Pipeline Update 2015

Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic...

June 2015
FROM

A Competitive Analysis of the Global Breast Cancer Therapeutics Market

The study assesses marketed and investigational products and combination regimens for the global breast cancer therapeutics market. Segmentation by drug class is provided, along with supporting information,...

March 2015
FROM

Breast Cancer Drug Pathway Analyzer 2015

Extra value: One year of free online updates included with this product There are today at least 567 targeted molecular therapies known to affect more than 256 specific intracellular signaling pathways...

January 2015
FROM

Global Breast Cancer Epidemiology and Patient Flow Analysis - 2015

The author announced the results of its Breast Cancer patient population study in a new report ‘Global Breast Cancer Epidemiology and Patient Flow Analysis - 2015’. The report provides insights into...

January 2015
FROM

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast...

September 2014
FROM

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Herceptin (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Herceptin (HER2-Positive Breast Cancer)...

September 2014
FROM

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Neratinib (HER2-Positive Breast Cancer)...

September 2014
FROM

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Perjeta (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Perjeta (HER2-Positive Breast Cancer) -...

September 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary The publisher has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) -...

September 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - China Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023

PharmaPoint: HER2-Positive Breast Cancer - US Drug Forecast and Market Analysis to 2023 Summary HER2-positive breast cancer is the second most common cancer in the world and the most common cancer...

September 2014
FROM
Loading Indicator

Our Clients

C.R. Bard, Inc. GlaxoSmithKline PLC Hologic Corporation Provista Diagnostics, Inc. Roche Diagnostics Ltd. Genomic Health Inc.